# Cloudbreak Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cloudbreak-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Irvine, US
- Website: www.cloudbreaktherapeutics.com
- Total disclosed funding: $171M
- Latest round: Series C (Jan 1, 2022)
- Investors on record: 15

## About

Based in Irvine, US and established in 2015, Cloudbreak Pharmaceutical is a pharmaceutical company that provides ocular drug development to treat eye diseases. The company developed drugs to treat eye diseases and drug candidates was approved, completed proof-of-concept (POC) phase II clinical, and carried out phase III clinical trials, product registration, and commercialization. The company takes contract research organizations (CRO) for non-clinical, chemistry, manufacturing and controls (CMC) and clinical development to realize maximize capital for drug development. The company developed ocular drug to treat eye diseases, including pterygium, meibomian gland dysfunction associated dry eye disease, pinguecula, glaucoma filtration surgery, wet age related macular degeneration, and myopia progression. The company's product pipeline includes CBT-001, CBT-006, CBT-004, CBT-007, CBT-005, CBT-009. CBT-001 is a potent multi-kinase inhibitor. CBT-006 is a molecule that can sequester cholesterol. CBT-009 is a ophthalmic formulation of atropine. The CBT-001, CBT-006, and CBT-004 is in clinical study phase II. The company plans to promote clinical study, registration, and commercialization of multiple product pipelines, to build GMP plant, and to introduce talents. The company generates revenue from pharmaceutical partnerships, licensing agreements, milestone payments, and anticipates future income from drug commercialization, especially through proprietary ophthalmic products advancing through late-stage trials. In July 2025, Cloudbreak Pharmaceutical raised HKD 611.88 million in IPO, selling 60.6 million shares at HKD 10.10 per share on the Hong Kong Exchanges and Clearing Limited, under ticker 2592.

## Funding rounds

- Series C, Jan 1, 2022, $130M — CCB International Asset Management, GTJA Investment Group, CDF-Capital, China Grand Pharmaceutical and Healthcare Holdings Limited, Efung Capital, DYEE Capital, Yingke Private Equity, CDH Baifu Capital, Industrial Securities Capital, Guanzi Private Equity Management (Hangzhou), Guangdong Yuejun Investment
- Series B, Apr 16, 2020, $25M — BOC International, China Grand Pharmaceutical and Healthcare Holdings Limited, V-Capital, Haoyue Capital
- Series A, Oct 25, 2018, $16M — HY Capital

## Investors

- HY Capital (https://capitalatlas.ai/funds/hy-capital) — Series A
- BOC International (https://capitalatlas.ai/funds/boc-international) — Series B
- China Grand Pharmaceutical and Healthcare Holdings Limited — Series B, Series C
- V-Capital (https://capitalatlas.ai/funds/v-capital) — Series B
- Haoyue Capital (https://capitalatlas.ai/funds/haoyue-capital) — Series B
- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series C
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series C
- CDF-Capital (https://capitalatlas.ai/funds/cdf-capital) — Series C
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series C
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series C
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series C
- CDH Baifu Capital (https://capitalatlas.ai/funds/cdh-baifu-capital) — Series C
- Industrial Securities Capital — Series C
- Guanzi Private Equity Management (Hangzhou) — Series C
- Guangdong Yuejun Investment — Series C